Neuronal nicotinic acetylcholine receptors (nAChRs) are
widely distributed in the CNS and have been proposed as
potential therapeutic targets for Alzheimer disease.
Selective α7 and α4β2 nicotinic acetylcholine
receptor (nAChR) agonists mediate improvement in attention,
learning and working memory.
Links between heavy smoking in midlife and increased risk of
developing AD and vascular dementia has recently been
reported (Rusanen et al., 2010). These data further support
the testing of the smoking cessation agent varenicline in
AD. See Alzforum
News 'Risk to Your Cognition: Sepsis, Smoking Wreak Havoc